Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 2/2015

01-02-2015 | Breast Cancer (B Overmoyer, Section Editor)

Unique Aspects of Caring for Young Breast Cancer Patients

Authors: Raina M. Ferzoco, Kathryn J. Ruddy

Published in: Current Oncology Reports | Issue 2/2015

Login to get access

Abstract

Breast cancer is the most commonly diagnosed malignancy in young women in the USA. Although breast cancer mortality has decreased overall, survival rates in young women remain lower than those in older women. Young women with breast cancer comprise a special population due to the aggressive biology of their tumors as well as their unique psychosocial concerns. Although general treatment principles are similar regardless of age, recent developments from research focused on younger women have provided new insights to guide treatment of this special population. This article will focus on these new developments in areas including endocrine therapy and fertility preservation as well as the unique treatment-related sequelae and psychosocial concerns among young women with breast cancer face.
Literature
1.
Siegel R et al. Cancer statistics. CA: Cancer J Clin. 2014;64(1):9–29.
2.
DeSantis C et al. Breast cancer statistics. CA: Cancer J Clin. 2014;64(1):52–62.
3.
4.
5.
Gnerlich JL et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7.CrossRefPubMedCentralPubMed
6.
Bleyer A et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8(4):288–98.CrossRefPubMed
7.
8.
Collins LC et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131(3):1061–6.CrossRefPubMed
9.
10.
Partridge AH et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol. 2013;31(21):2692–8.CrossRefPubMed
11.
12.
Ruddy KJ et al. Breast cancer presentation and diagnostic delays in young women. Cancer. 2014;120(1):20–5.CrossRefPubMed
13.
Fisher B et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed
14.
van Dongen JA et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143–50.CrossRefPubMed
15.
Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet, 2000. 355(9217): p. 1757-70.
16.
Botteri E et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol. 2010;21(4):723–8.CrossRefPubMed
17.
Kurtz JM et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol. 1990;8(4):591–8.PubMed
18.
Voogd AC et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688–97.PubMed
19.
Mahmood U et al. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1387–93.CrossRefPubMed
20.•
Partridge AH et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209–20. Young women with breast cancer comprise a special population due to their unique needs. Little research has been done specifically targeting this group. These guidelines provide treatment recommendations specific to this vulnerable population as well as identify areas for further research.CrossRefPubMed
21.
22.
Jones NB et al. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol. 2009;16(10):2691–6.CrossRefPubMed
23.
Katipamula R et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol. 2009;27(25):4082–8.CrossRefPubMedCentralPubMed
24.
Pesce, C.E., et al., Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base. Journal of the American College of Surgeons, 2014
25.
Rosenberg S, S.K., Ruddy K, et al., Factors associated with contralateral prophylactic mastectomy in young women with breast cancer [abstract]. In 36th Annual San Antonio Breast Cancer Symposium 2013: San Antonio, TX.
26.
Hughes KS et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7.CrossRefPubMedCentralPubMed
27.
Darby S et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRefPubMed
28.
Poortmans PM et al. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 “boost versus no boost” trial. Cancer Radiother. 2008;12(6–7):565–70.CrossRefPubMed
29.
Antonini N et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol. 2007;82(3):265–71.CrossRefPubMed
30.
Pan IW, Smith BD, Shih YC. Factors contributing to underuse of radiation among younger women with breast cancer. J Natl Cancer Inst. 2014;106(1):djt340.CrossRefPubMedCentralPubMed
31.
Ciammella P et al. Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors. Radiat Oncol. 2014;9(1):97.CrossRefPubMedCentralPubMed
32.
Darby SC et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.CrossRefPubMed
33.
Sikov W, B.D., Perou C. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). in 36th Annual San Antonio Breast Cancer Symposium. 2013. San Antonio, TX.
34.
Davies C et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.CrossRefPubMed
35.••
Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16. The ATLAS trial demonstrated statistically significant improvements in breast cancer recurrence and breast cancer-related death when adjuvant tamoxifen was continued for 10 versus 5 years. This provides young women with another treatment option for adjuvant endocrine therapy which must be weighed against the potential side effects of long-term hormonal therapy.CrossRefPubMedCentralPubMed
36.
Gray RG et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. ASCO Meet Abstract. 2013;31(18_suppl):5.
37.
38.
Decensi A et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111(5):650–6.CrossRefPubMed
39.••
Pagani, O., et al., Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. The New England Journal of Medicine, 2014. The combined results of the TEXT and SOFT trials showed that an aromatase inhibitor plus ovarian function suppression significantly reduced breast cancer recurrence when compared to tamoxifen plus ovarian function suppression in premenopausal women with hormone receptor-positive breast cancer. These results provide premenopausal women with hormone receptor-positive breast cancer with a new adjuvant treatment option, previously only available to postmenopausal women
40.
Bernhard J et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). ASCO Meet Abstract. 2014;32(15_suppl):557.
41.
Coleman R, G.M., Paterson A, et al, Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. In 36th Annual San Antonio Breast Cancer Symposium 2013: San Antonio, TX.
42.••
Gnant M et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–41. This study by Gnant et al. demonstrated a significant disease-free survival benefit with the addition of zoledronic acid to anastrazole or tamoxifen, suggesting that premenopausal women with early-stage breast cancer should receive zoledronic acid in addition to adjuvant endocrine therapy.CrossRefPubMed
43.
Howard-Anderson J et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(5):386–405.CrossRefPubMed
44.
Schag CA et al. Assessing problems of cancer patients: psychometric properties of the cancer inventory of problem situations. Health Psychol. 1990;9(1):83–102.CrossRefPubMed
45.
Rosenberg, S.M., et al., Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer, 2014
46.
Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol. 2008;26(5):753–8.CrossRefPubMed
47.
Mortimer JE et al. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol. 1999;17(5):1488–92.PubMed
48.
Ruddy KJ et al. Young women with breast cancer: a focus group study of unmet needs. J Clin Oncol. 2013;2(4):153–60.
49.
Baucom DH et al. Psychosocial issues confronting young women with breast cancer. Breast Dis. 2005;23:103–13.PubMed
50.
Compas BE et al. Adjustment to breast cancer: age-related differences in coping and emotional distress. Breast Cancer Res Treat. 1999;54(3):195–203.CrossRefPubMed
51.
Partridge AH et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–83.CrossRefPubMed
52.
53.
Ganz PA et al. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21(22):4184–93.CrossRefPubMed
54.
Vanlemmens L et al. The subjective quality of life of young patients with breast cancer and their partners. ASCO Meet Abstracts. 2014;32(15_suppl):9569.
55.
Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol. 2005;23(4):766–73.CrossRefPubMed
56.
57.•
Ruddy KJ et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151–6. The possibility of infertility is a major cause for concern in many young women with breast cancer. This study looked at how fertility concerns affect treatment-related decision making in young women and demonstrated that while some women take these concerns into consideration when choosing treatments, few pursue fertility preservation prior to treatment initiation.CrossRefPubMed
58.
Moore HCF et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: an international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). ASCO Meet Abstracts. 2014;32(15_suppl):LBA505.
Metadata
Title
Unique Aspects of Caring for Young Breast Cancer Patients
Authors
Raina M. Ferzoco
Kathryn J. Ruddy
Publication date
01-02-2015
Publisher
Springer US
Published in
Current Oncology Reports / Issue 2/2015
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-014-0425-x

Other articles of this Issue 2/2015

Current Oncology Reports 2/2015 Go to the issue

Breast Cancer (B Overmoyer, Section Editor)

Assessing the Role of Platinum Agents in Aggressive Breast Cancers

Breast Cancer (B Overmoyer, Section Editor)

Immunotherapy for the Treatment of Breast Cancer

Breast Cancer (B Overmoyer, Section Editor)

Targeting the Androgen Receptor in Breast Cancer

Palliative Medicine (A Jatoi, Section Editor)

Respecting the Spiritual Side of Advanced Cancer Care: a Systematic Review

Genitourinary Cancers (E Jonasch, Section Editor)

Testicular Choriocarcinoma: a Rare Variant that Requires a Unique Treatment Approach
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits